Returns From Sanofi Consumer Expansion Could Point To More

The French pharma's strategy of driving consumer health business growth by expanding the product lineup played out during the first quarter with the launch of OTC switch Xyzal Allergy and with further integration of OTC drug and vitamin brands recently acquired from Boehringer Ingelheim.

Sanofi's launch of Xyzal Allergy 24HR in the US helped remedy its slumping consumer health product business with more than $43m sales in the first quarter as the division's overall revenues grew nearly 5% to $1.5bn.

The French pharma's strategy of driving consumer health business growth by expanding the product lineup played out during the first...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Rx-to-OTC Switch

More from Health